Clozaril, an atypical antipsychotic, did not gain approval for use in Australia until 1992.
Prior to its general release, a trial was conducted in three pilot sites to test efficacy of a monitoring system.
Fear of litigation among hospital staff was reduced through educational sessions that reported on the low incidence of serious side effects and the efficacy of the monitoring system.
The most common side effect noted with initiation of Clozaril was sedation, which persisted for 4 to 6 weeks.
Subsequent side effects included drowsiness, increased salivation, and tachycardia.
Mots-clés Pascal : Clozapine, Neuroleptique, Psychotrope, Chimiothérapie, Traitement, Attitude, Personnel sanitaire, Australie, Océanie, Education sanitaire, Programme thérapeutique, Homme
Mots-clés Pascal anglais : Neuroleptic, Psychotropic, Chemotherapy, Treatment, Attitude, Health staff, Australia, Oceania, Health education, Therapeutic schedule, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0282523
Code Inist : 002B02B03. Création : 01/03/1996.